Hyperhomocysteinemia in a Mild Cognitive Impairment and Dementia Population: the Effect of Treatment With Cerefolin NAC® in a Naturalistic Community-based Dementia Practice
Hyperhomocysteinemia in a Mild Cognitive Impairment and Dementia Population: the Effect of Treatment With Cerefolin NAC® in a Naturalistic Community-based Dementia Practice
This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this naturalistic grouping of patients with various stages of cognitive loss and diagnosed with various types of dementia.
A single-center, retrospective review of the medical charts of 700 de-identified elderly patients who underwent evaluation and treatment for cognitive loss including analysis of:
Laboratory values of interest: homocysteine, methylmalonic acid, CRP, BNP, CO2, TSH, Fe/TIBC, RPR/TPPA/FTA-ABS, and if available, folic acid and B12 levels ordered by primary care providers.
Neuropsychological tests of executive function, memory and affect:
Wechsler Memory Scale-Revised (WMS-R) or Fourth Edition (WMS-IV)
Shopping List Test, Delayed Recall
Trailmaking A and B Tests
Verbal Absurdities subtest of the Stanford Binet, Form L-M
Proverbs Test
Memory Orientation Screening Test
Folstein Mini-Mental State Exam
Geriatric Depression Scale, 15 items
Sub-group analysis of MRI volumetrics and PET scans when available. Sequentially pulled from June 1, 2009 to September 2011
Inclusion Criteria:
Exclusion Criteria: